1. Home
  2. Journals
  3. Biomedical Research and Clinical Advancements
  4. Current Issues
  Submit Manuscript

Research Article | DOI: https://doi.org/BRCA-RA-26-42

Antiviral therapies for hepatitis C infection: current and new developments

Hari Prasad Sonwani *

Apollo College of Pharmacy, Anjora Durg 491001(C.G),India 

*Corresponding Author: Hari Prasad Sonwani. Apollo College of Pharmacy, Anjora Durg 491001(C.G),India

Citation: Hari Prasad Sonwani (2026). Antiviral therapies for hepatitis C infection: current and new developments, J Biomedical Research and Clinical Advancements; 3 (1) 42, DOI: BRCA-RA-26-42

Copyright: Hari Prasad Sonwani, et al © (2026). This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 12 February 2026 | Accepted: 22 February 2026 | Published: 28 February 2026

Keywords: antiviral therapy; direct acting antiviral; hepatitis C virus; polymerase inhibitors; protease inhibitors

Abstract

The majority of HCV strains in Europe and North America are genotype-1, and up to 75% of individuals with chronic infection can be cured with recently approved direct acting antivirals. New antiviral treatments offer longer treatment durations, better tolerability, increased virological response, and possibly even the opportunity to stop using interferon. The primary treatment drugs, such as telaprevir and boceprevir, that are currently part of the standard of care are highlighted in this study. It then assesses the mechanisms underlying newly developed medications, as well as the response rates observed in existing research. Lastly, it looks ahead to the not-too-distant future to examine treatment plans that include interferon-free medicines and agent combinations, and in which patients They could end up being the most successful.

References

  1. Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med 2012; 366: 273–275.
    View at Publisher | View at Google Scholar
  2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529–538.
    View at Publisher | View at Google Scholar
  3. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29: 74–81.
    View at Publisher | View at Google Scholar
  4. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271–278.
    View at Publisher | View at Google Scholar
  5. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237–244.
    View at Publisher | View at Google Scholar
  6. Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol 2011; 8: 212–223.
    View at Publisher | View at Google Scholar
  7. Noureddin M, Ghany MG. Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C. Gastroenterol Clin North Am 2010; 39: 649–658.
    View at Publisher | View at Google Scholar
  8. Reddy KR, Nelson DR, Zeuzem S. Ribavirin: current role in theoptimal clinical management of chronic hepatitis C. Hepatol 2009; 50: 402–411.
    View at Publisher | View at Google Scholar
  9. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52: 889–900.
    View at Publisher | View at Google Scholar
  10. Grebely J, Matthews GV, Dore GJ. Treatment of acute HCV infection. Nat Rev Gastroenterol Hepatol 2011; 8: 265–274.
    View at Publisher | View at Google Scholar
  11. Doyle JS, Sacks-Davis R, Hellard ME. Acute hepatitis C infection: new approaches to surveillance, treatment and prevention. Curr Hepatitis Rep 2012; doi: 10.1007/s11901-012-0143-5. in press.
    View at Publisher | View at Google Scholar
  12. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.
    View at Publisher | View at Google Scholar
  13. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
    View at Publisher | View at Google Scholar
  14. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action ofribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002–1009.
    View at Publisher | View at Google Scholar
  15. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399–401.
    View at Publisher | View at Google Scholar
  16. Holmes JA, Sievert W, Thompson AJ. IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection. Biomark Med 2011; 5: 461–478.
    View at Publisher | View at Google Scholar
  17. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA
    View at Publisher | View at Google Scholar
  18. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, Herrmann E, Lotsch J, Berg T. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415–421.
    View at Publisher | View at Google Scholar
  19. Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010; 32: 2117–2138.
    View at Publisher | View at Google Scholar
  20. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49: 634–651.
    View at Publisher | View at Google Scholar
  21. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245–264.
    View at Publisher | View at Google Scholar
  22. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 600–609.
    View at Publisher | View at Google Scholar
  23. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645–652.
    View at Publisher | View at Google Scholar
  24. Camma C, Cabibbo G, Bronte F, Enea M, Licata A, Attanasio M, Andriulli A, Craxi A. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis. J Hepatol 2009; 51: 675–681.
    View at Publisher | View at Google Scholar
  25. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandao-Mello CE, Reddy KR, Craxi A, Martin AO, Teuber G, Messinger D, Thommes JA, Tietz A. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009; 150: 528–540.
    View at Publisher | View at Google Scholar
  26. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Goncales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 1618–1628.
    View at Publisher | View at Google Scholar
  27. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438–450.
    View at Publisher | View at Google Scholar
  28. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561–573.
    View at Publisher | View at Google Scholar
  29. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, Yeung B, Marks P, Van Beek I, McCaughan G, White P, French R, Rawlinson W, Lloyd AR, Kaldor JM. Effective treatment of injecting drug users with recently acquired hepatitis C virus Infection. Gastroenterology 2010; 138: 123–135.
    View at Publisher | View at Google Scholar
  30. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis Cvirus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132: 1979–1998.
    View at Publisher | View at Google Scholar
  31. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nature reviews. Microbiology 2007; 5: 453–463.
    View at Publisher | View at Google Scholar
  32. Jazwinski AB, Muir AJ. Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals. Gastroenterol Clin North Am 2011; 40: 481–494.
    View at Publisher | View at Google Scholar
  33. Pockros PJ. New direct-acting antivirals in the development for hepatitis C virus infection. Therap Adv Gastroenterol 2010; 3: 191–202.
    View at Publisher | View at Google Scholar
  34. Lee LY, Tong CY, Wong T, Wilkinson M. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials. Int J Clin Pract 2012; 66: 342–355.
    View at Publisher | View at Google Scholar
  35. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195–1206.
    View at Publisher | View at Google Scholar
  36. Foote BS, Spooner LM, Belliveau PP. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother 2011; 45: 1085–1093.
    View at Publisher | View at Google Scholar
  37. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, KareyU, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50: 1709–1718.
    View at Publisher | View at Google Scholar
  38. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767–1777.
    View at Publisher | View at Google Scholar
  39. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207–1217.
    View at Publisher | View at Google Scholar
  40. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705–716.
    View at Publisher | View at Google Scholar
  41. Vierling JM. Efficacy of boceprevir in prior null responders to peginterferon/ribavirin: the PROVIDE Study. Hepatology 2011; 54 (Suppl. 1): A931.
    View at Publisher | View at Google Scholar
img

Harry Brooks

journal of Clinical Case Studies and Review Reports. I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office.the reviewer board were accurate and helpful regarding anu modifications for my manuscript,and the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help.it was my pleasure to contribute with your promising journal and i am looking forward for more collaboration.

img

Mark

My testimonial covering : the peer review process is qucick and effective,the support from the editorial office is very professional and friendly, quality of the Clinical Case Studies and Review Reports is scientific and publishers research.

img

Sinisa franjic

i would like to thank the editorial team for their timely responses and consideration in the publication of my paper . I would encourage to publish there research in ScienceFrontier.

img

Ritu Tiwari

I am pleased to submit my testimonials regarding the reviewer board and the editorial office. As a peer reviewer for the manuscript titled “A Novel Dissolution Method for Simultaneous Estimation of sennoside A and Sennoside B in Senna Tablet,” I was consistently impressed by the reviewers’ thorough analysis, insightful feedback, and unwavering commitment to enhancing the quality of the work. Their reviews were comprehensive and characterized by a respectful and collaborative approach, providing valuable suggestions that significantly improved the paper's outcome. Their dedication to the peer review process demonstrated their expertise and steadfast pursuit of excellence.

img

Qader Bawerdi

With all due respect, I would like to express my opinion on the peer review, editorial support, and the quality of the journal as follows: The peer review was conducted quickly and with great care, and my article was accepted for publication in less than a week. The editorial support regarding the status of the article process was excellent, and they informed me every day until the acceptance of the current status of the article version, and regarding how to answer questions, the editorial support was excellent, timely, and friendly, and they answered questions as soon as possible and did not hesitate. The quality of the journal was excellent and it made me proud to be acquainted with the journal, and I sincerely look forward to extensive scientific collaborations in any field. I hope for increasing success and pride for the International Journal of Social Science Research and Review and all scientific and knowledge-based communities. Thank you

img

Bhuvanagiri Sathya Sindhuja

"I would like to express my sincere appreciation for the opportunity to contribute to this esteemed journal. The publication process was smooth, well-coordinated, and the peer reviewers deemed highly professional. The editorial team demonstrated exceptional diligence and support at every stage, ensuring a seamless experience from submission to final publication. I am truly honored to be featured in such a reputable platform and look forward to future collaborations."

img

Safana Abdullah Algutaini

Testimonial for the Journal of Biomedical Research and Clinical Advancements It was a truly rewarding experience publishing our study, "Single-Surgeon Outcomes of Left Ventricular Aneurysm Repair in Wartime Syria: A 10-Year Retrospective Study at Damascus University Cardiac Surgery Hospital," with the Journal of Biomedical Research and Clinical Advancements. The editorial and peer-review process was both rigorous and efficient, demonstrating a high standard of academic integrity and scientific scrutiny. The journal’s commitment to open access and global health equity is evident in its support of research emerging from conflict-affected and resource-limited settings—making our work not only visible but impactful. The professionalism of the editorial team, the speed of communication, and the clarity of submission guidelines all contributed to a smooth publication process. We were particularly impressed by the quality of the publication layout and the prompt indexing of our article, which enhances its accessibility to clinicians, researchers, and policymakers worldwide. We are proud to have contributed to this journal and highly recommend it to fellow researchers seeking a reputable platform to disseminate clinically significant and globally relevant findings.

img

Sajjad Ur Rahman

It is a great pleasure and honour to write this testimonial for IJPHRE which published our article on TH for HIE in LMIC on Feb 16th, 2026 and a commentary article on the same subject on 31st January 2025. Going through the very fast, well supported and properly guided process of publication in IJPHRE was an exceptional experience. The submission was very quick; peer review was very professional and done within a reasonable and short time. The comments of the reviewers meaningfully helped to reshape the manuscript without changing the fundamental dataset and analysis. The editorial board was very helpful and supportive. The communication was clear and instant, almost on daily basis. The team of authors felt very proud of seeing its manuscript published in an international journal of very high quality and esteem in remarkably short time of almost 45 days. We highly recommend IJPHRE for publication of all kinds of original scientific research, review articles and clinical guidelines.